Table 3—

Results of 3-month additional treatment with pioglitazone in the study patients divided into two subgroups

VariablesNonresponders (n = 30)
Responders (n = 40)
Baseline3 monthsBaseline3 months
Sex (male/female)12/1820/20
Age (years)60.4 ± 2.161.8 ± 1.6
BMI (kg/m2)22.7 ± 0.623.0 ± 0.623.9 ± 0.523.9 ± 0.5
SBP (mmHg)144 ± 4143 ± 3144 ± 3146 ± 3
DBP (mmHg)80 ± 280 ± 282 ± 283 ± 3
FPG (mmol/l)9.4 ± 0.58.9 ± 0.49.7 ± 0.57.3 ± 0.4
HbA1c (%)7.8 ± 0.27.7 ± 0.28.3 ± 0.16.8 ± 0.1
IRI (pmol/l)49.7 ± 4.9646.8 ± 4.7563.3 ± 5.7655.5 ± 8.42
HOMA-IR2.96 ± 0.382.62 ± 0.31*3.65 ± 0.421.97 ± 0.16
Total cholesterol (mmol/l)5.40 ± 0.125.42 ± 0.115.51 ± 0.155.27 ± 0.16*
LDL cholesterol (mmol/l)3.32 ± 0.093.27 ± 0.093.30 ± 0.113.09 ± 0.12*
HDL cholesterol (mmol/l)1.37 ± 0.081.43 ± 0.081.50 ± 0.071.51 ± 0.07
Triglycerides (mmol/l)1.54 ± 0.061.56 ± 0.051.57 ± 0.051.46 ± 0.06*
Adiponectin (μg/ml)5.98 ± 0.527.48 ± 0.716.07 ± 0.468.08 ± 0.73
Leptin (ng/ml)6.16 ± 0.796.21 ± 0.776.79 ± 0.666.95 ± 0.56
  • Data are means ± SEM.

  • *

    * P < 0.05,

  • P < 0.01 vs. baseline values;

  • P < 0.05 vs. nonresponders.